

## **Ongoing Disclosure Notice**

## Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	The a2 Milk Company Limited (ATM)
Date this disclosure made:	06-Sep-2024
Date of last disclosure:	29-Nov-2023
Director or senior manager giving disclosure	
Full name(s):	Jaron James McVicar
Name of listed issuer:	The a2 Milk Company Limited
Name of related body corporate (if applicable):	N/A
Position held in listed issuer:	Chief Legal and Sustainability Officer &
	Company Secretary
Summary of acquisition or disposal of relevant interest (excluding sp	ecified derivatives)
	(1) Unlisted performance rights
	(Performance Rights) representing an
Class of affected quoted financial products:	entitlement to acquire fully paid ordinary shares in ATM ( <b>Ordinary</b>
	Shares).
	(2) Ordinary Shares.
	(1) (a) and (b) Registered holder and
	beneficial owner
Nature of the affected relevant interest(s):	(1)(c) Spouse of registered holder and
	beneficial owner
	(2) Registered holder and beneficial owner
	OWNER
For that relevant interest-	
	(1) 214,136 Performance Rights of
	which:
	(a) 61,787 are due to vest on a date
Number held in class before acquisition or disposal:	to be determined by the Board following
	the release of ATM's full year audited results for FY2024 provided certain
	performance conditions are met;
	(b) 63,159 are due to vest on a date
	to be determined by the Board following
	the release of ATM's full year audited
	results for FY2025 provided certain
	performance conditions are met; and
	(c) 89,190 are due to vest on a date to be determined by the Board following
	the release of ATM's full year audited
	results for FY2026 provided certain
	performance conditions are met.
	(2) 97,843 Ordinary Shares.

Number held in class after acquisition or disposal:	(1) 152,349 Performance Rights of which:  (a) 63,159 are due to vest on a date to be determined by the Board following the release of ATM's full year audited results for FY2025 provided certain performance conditions are met.  (b) 89,190 are due to vest on a date to be determined by the Board following the release of ATM's full year audited results for FY2026 provided certain performance conditions are met.  (2) 159,630 Ordinary Shares.
Current registered holder(s):	(1)(a), (1)(b) and (2) Jaron James McVicar (1)(c) Charlotte Mary McVicar
Registered holder(s) once transfers are registered:	(1)(a) and (2) Jaron James McVicar (1)(b) Charlotte Mary McVicar
Summary of acquisition or disposal of specified derivatives relevant interest (if ap	oplicable)
Type of affected derivative:	N/A
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying	N/A
financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal  Total number of transactions to which notice relates:	1
Details of transactions requiring disclosure-	
Date of transaction:	30-Aug-2024
Nature of transaction:	Vesting and automatic exercise of 61,787 Performance Rights, resulting in the transfer of 61,787 Ordinary Shares to Jaron James McVicar
Name of any other party or parties to the transaction (if known):	a2 ESS Holdings Pty Limited as trustee for a2 Group Employee Share Trust (transferor of Ordinary Shares)
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	Nil
converted into a cash value, describe the consideration.	

Number of financial products to which the transaction related:	(1) 61,787 Performance Rights (2) 61,787 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	modical.
Date of signature:	3 September 2024
or	,
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	